SOURCE: Goldman Small Cap Research, Inc.

September 12, 2013 09:33 ET

Nuvilex Forms Key Alliance With Industry Leader

BALTIMORE, MD--(Marketwired - Sep 12, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that earlier this week, Nuvilex, Inc. (OTCQB: NVLX) announced it had entered into a contract with Fisher BioServices, Inc., a part of medical services giant Thermo Fisher Scientific, Inc. for the long-term storage of cells that will be required for future Phase III clinical trials in pancreatic cancer and for studies in other cancers. This is a huge deal for Nuvilex and demonstrates how far along the Company is in clinical trial development, which should act as a catalyst to move the stock's valuation significantly higher.

Fisher BioServices is one of the leading companies in critical biological material management and cell and tissue storage with facilities around the world. Over its 28-year history, Fisher BioServices has stored more than 170 million biospecimens, including cells and tissues, as well as their associated data. Importantly, their facilities are fully GMP compliant -- a requirement for an NDA filing. Clearly, having a major player like Fisher Bioservices, Inc. as a partner will help ensure that the Phase III trials can be carried out smoothly and thus facilitate the transition into an NDA filing.

The Fisher BioServices facility, located in Rockville, Maryland, is just a few miles from Nuvilex's International Headquarters, and will be used as one of several cell storage sites around the world holding the cells to be encapsulated that are part of Nuvilex's pancreatic cancer treatment. Multi-site storage of the critically important cells is Standard Operating Procedure for companies, such as Nuvilex, that are engaged in the use of cells for therapeutic purposes.

The cells to be stored in the Fisher BioServices facilities are the same cells as those used in the previous clinical trials for advanced, inoperable pancreatic cancer that were done with the live-cell encapsulation technology recently acquired by Nuvilex. They will be maintained in the facility and can be propagated in the event of a loss in the system somewhere else to obtain cells for encapsulation as needed for clinical trials, including those to be employed in the Company's pancreatic cancer treatment.

This partnership is a critical step for Nuvilex and confirms the Company's status as a well-regarded player in the cancer treatment development segment. By entering into a relationship with the industry leader, whose parent employs tens of thousands of employees around the world, Nuvilex is making a statement to the industry and its shareholders that the Company is dedicated to reaching its clinical trials objectives as quickly as possible.

To view all of our sponsored Nuvilex reports, updates, articles, disclosures and disclaimers, or to download the article in its entirety, please visit

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. For more information visit:

Contact Information